Limits...
Increased chitotriosidase activity in plasma of patients with type 2 diabetes

View Article: PubMed Central - PubMed

ABSTRACT

Introduction: Chitotriosidase (CHIT1) is a chitinolytic enzyme involved mainly in the immune and inflammatory response. It shows increased activity in many pathologies, including in newly diagnosed type 2 diabetes (T2D). This study aimed to investigate this enzyme's activity in plasma of patients with ongoing T2D and indicate factors related to the increased activity of this enzyme.

Material and methods: Ninety-one patients and 46 control subjects without abnormalities in carbohydrate metabolism and inflammatory states were enrolled in the study. Plasma CHIT1 activity was measured by a spectrofluorometric method. Routine laboratory parameters such as blood glucose, total cholesterol and HDL fraction, triglyceride, glycated hemoglobin, white blood cell count and C-reactive protein were measured by standard methods.

Results: We found that the chitotriosidase activity was significantly higher (p < 0.001) in type 2 diabetic patients and positively associated with parameters of glycemic control (levels of glucose and glycated hemoglobin) and blood pressure. Plasma glucose level and systolic blood pressure were independent determinants of increased CHIT1 activity in T2D patients, even after adjustment for disease duration, body mass index, parameters of inflammation and lipid metabolism. We also found that increased CHIT1 activity was associated with occurrence of diabetic angiopathies.

Conclusions: This investigation indicates a possible role of chitotriosidase in the course of T2D, especially in relation to development of diabetic angiopathies.

No MeSH data available.


Related in: MedlinePlus

Chitotriosidase activity in examined population and in different subgroups of diabetic patients. First two bars illustrate activity of chitotriosidase in all patients with type 2 diabetes and controls. Next bars illustrate activity of chitotriosidase in distinguished subgroups of diabetic patients: a) patients with obesity, overweight and normal weight, b) patients with and without dyslipidemia, c) patients with poor and good short-term glycemic control, d) patients with poorly controlled hypertension and normalized blood pressure, e) patients with and without symptoms of inflammation, f) smokers and non-smokers, g) patients treated with insulin or insulin with oral antidiabetic drugs (OADs); ns – not statistically significant
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5016580&req=5

Figure 0001: Chitotriosidase activity in examined population and in different subgroups of diabetic patients. First two bars illustrate activity of chitotriosidase in all patients with type 2 diabetes and controls. Next bars illustrate activity of chitotriosidase in distinguished subgroups of diabetic patients: a) patients with obesity, overweight and normal weight, b) patients with and without dyslipidemia, c) patients with poor and good short-term glycemic control, d) patients with poorly controlled hypertension and normalized blood pressure, e) patients with and without symptoms of inflammation, f) smokers and non-smokers, g) patients treated with insulin or insulin with oral antidiabetic drugs (OADs); ns – not statistically significant

Mentions: Plasma chitotriosidase activities in patients with type 2 diabetes mellitus and control subjects are presented in Figure 1 (first two bars). A statistically significant (p < 0.001) increase of CHIT1 activity (over 70%) was observed in type 2 diabetic patients compared with the control subjects. No significant differences in CHIT1 activity were observed in subgroups of diabetic patients divided according to BMI value, as well as in subgroups created on the basis of presence of dyslipidemia and inflammation. Neither tobacco use nor applied hypoglycemic treatment had an influence on activity of this enzyme.


Increased chitotriosidase activity in plasma of patients with type 2 diabetes
Chitotriosidase activity in examined population and in different subgroups of diabetic patients. First two bars illustrate activity of chitotriosidase in all patients with type 2 diabetes and controls. Next bars illustrate activity of chitotriosidase in distinguished subgroups of diabetic patients: a) patients with obesity, overweight and normal weight, b) patients with and without dyslipidemia, c) patients with poor and good short-term glycemic control, d) patients with poorly controlled hypertension and normalized blood pressure, e) patients with and without symptoms of inflammation, f) smokers and non-smokers, g) patients treated with insulin or insulin with oral antidiabetic drugs (OADs); ns – not statistically significant
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5016580&req=5

Figure 0001: Chitotriosidase activity in examined population and in different subgroups of diabetic patients. First two bars illustrate activity of chitotriosidase in all patients with type 2 diabetes and controls. Next bars illustrate activity of chitotriosidase in distinguished subgroups of diabetic patients: a) patients with obesity, overweight and normal weight, b) patients with and without dyslipidemia, c) patients with poor and good short-term glycemic control, d) patients with poorly controlled hypertension and normalized blood pressure, e) patients with and without symptoms of inflammation, f) smokers and non-smokers, g) patients treated with insulin or insulin with oral antidiabetic drugs (OADs); ns – not statistically significant
Mentions: Plasma chitotriosidase activities in patients with type 2 diabetes mellitus and control subjects are presented in Figure 1 (first two bars). A statistically significant (p < 0.001) increase of CHIT1 activity (over 70%) was observed in type 2 diabetic patients compared with the control subjects. No significant differences in CHIT1 activity were observed in subgroups of diabetic patients divided according to BMI value, as well as in subgroups created on the basis of presence of dyslipidemia and inflammation. Neither tobacco use nor applied hypoglycemic treatment had an influence on activity of this enzyme.

View Article: PubMed Central - PubMed

ABSTRACT

Introduction: Chitotriosidase (CHIT1) is a chitinolytic enzyme involved mainly in the immune and inflammatory response. It shows increased activity in many pathologies, including in newly diagnosed type 2 diabetes (T2D). This study aimed to investigate this enzyme's activity in plasma of patients with ongoing T2D and indicate factors related to the increased activity of this enzyme.

Material and methods: Ninety-one patients and 46 control subjects without abnormalities in carbohydrate metabolism and inflammatory states were enrolled in the study. Plasma CHIT1 activity was measured by a spectrofluorometric method. Routine laboratory parameters such as blood glucose, total cholesterol and HDL fraction, triglyceride, glycated hemoglobin, white blood cell count and C-reactive protein were measured by standard methods.

Results: We found that the chitotriosidase activity was significantly higher (p &lt; 0.001) in type 2 diabetic patients and positively associated with parameters of glycemic control (levels of glucose and glycated hemoglobin) and blood pressure. Plasma glucose level and systolic blood pressure were independent determinants of increased CHIT1 activity in T2D patients, even after adjustment for disease duration, body mass index, parameters of inflammation and lipid metabolism. We also found that increased CHIT1 activity was associated with occurrence of diabetic angiopathies.

Conclusions: This investigation indicates a possible role of chitotriosidase in the course of T2D, especially in relation to development of diabetic angiopathies.

No MeSH data available.


Related in: MedlinePlus